Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
暂无分享,去创建一个
P. Sonneveld | P. Moreau | T. Facon | M. Mateos | C. Hulin | A. Alegre | A. Lam | M. Hashim | Jianming He | T. Vincken | S. Côté | T. Kampfenkel